Injectable Amoxicillin Versus Injectable Ampicillin Plus Gentamicin in the Treatment of Severe Pneumonia in Children Aged 2 to 59 Months: Protocol for an Open-Label Randomized Controlled Trial

Lubaba Shahrin, Mohammod Jobayer Chisti, Abu Sadat Mohammad Sayeem Bin Shahid, Abu Sayem Mirza Mohammad Hasibur Rahman, Md Zahidul Islam, Farzana Afroze, Sayeeda Huq, Tahmeed Ahmed, Lubaba Shahrin, Mohammod Jobayer Chisti, Abu Sadat Mohammad Sayeem Bin Shahid, Abu Sayem Mirza Mohammad Hasibur Rahman, Md Zahidul Islam, Farzana Afroze, Sayeeda Huq, Tahmeed Ahmed

Abstract

Background: Pneumonia causes about 0.9 million deaths worldwide each year. The World Health Organization (WHO) guidelines for the standard management of severe pneumonia requires parenteral ampicillin every 6 hours and once-daily parenteral gentamicin for 5 to 7 days. Although this treatment has contributed to the reduction of mortality, it requires nursing interventions every 6 hours for 7 days. Further intervention trials should be conducted to search for alternate antibiotics with better adherence, reduced cost, and reduced hospital stay. Parenteral amoxicillin is an effective alternative to ampicillin, as it has a longer half-life and broader coverage.

Objective: The aim of this clinical trial is to compare the efficacy of a dose of injectable amoxicillin every 12 hours plus a once-daily dose of injectable gentamicin with a dose of injectable ampicillin every 6 hours plus a once-daily dose of injectable gentamicin in children hospitalized for severe pneumonia.

Methods: This randomized, controlled, open-label, noninferiority trial is being conducted in Dhaka Hospital of the International Centre for Diarrheal Disease Research, Bangladesh. A sample size of 308 children with severe pneumonia will give adequate power to this study. Children aged 2 to 59 months are randomized to either intravenous ampicillin or intravenous amoxicillin, plus intravenous gentamicin in both study arms. The monitoring of the patients is carried out according to the WHO protocol for the treatment of severe pneumonia. The primary objective is the rate of treatment failure, defined by the persistence of danger signs of severe pneumonia beyond 48 hours or deterioration within 24 hours of initiation of the therapy. The secondary objectives are (1) improvement in or the resolution of danger signs since enrollment, (2) length of hospital stay, (3) death during hospitalization, and (4) rate of nosocomial infections.

Results: Enrollment in the study started on January 1, 2018, and ended on October 31, 2019. Data entry and analysis are in progress. Findings from the study are expected to be disseminated in October 2020.

Conclusions: Our study's findings will improve compliance with the use of antibiotics that require less frequent doses for the treatment of severe pneumonia.

Trial registration: ClinicalTrials.gov NCT03369093; https://ichgcp.net/clinical-trials-registry/NCT03369093.

International registered report identifier (irrid): DERR1-10.2196/17735.

Keywords: amoxicillin; children; randomized controlled trial, Bangladesh; severe pneumonia; treatment failure.

Conflict of interest statement

Conflicts of Interest: None declared.

©Lubaba Shahrin, Mohammod Jobayer Chisti, Abu Sadat Mohammad Sayeem Bin Shahid, Abu Sayem Mirza Mohammad Hasibur Rahman, Md. Zahidul Islam, Farzana Afroze, Sayeeda Huq, Tahmeed Ahmed. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 02.11.2020.

Figures

Figure 1
Figure 1
Standard Protocol Items: Recommendation for Interventional Trials (SPIRIT) figure showing the schedule of enrollment, interventions, and assessments. IV: intravenous.
Figure 2
Figure 2
Flowchart for the proposed randomized controlled trial. IM: intramuscular; IV: intravenous.

References

    1. Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, Cousens S, Mathers C, Black RE. Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet. 2015 Jan 31;385(9966):430–40. doi: 10.1016/S0140-6736(14)61698-6.
    1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simões EAF, Rudan I, Weber MW, Campbell H. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010 May 01;375(9725):1545–55. doi: 10.1016/S0140-6736(10)60206-1.
    1. Feikin DR, Hammitt LL, Murdoch DR, O'Brien KL, Scott JAG. The Enduring Challenge of Determining Pneumonia Etiology in Children: Considerations for Future Research Priorities. Clin Infect Dis. 2017 Jun 15;64(suppl_3):S188–S196. doi: 10.1093/cid/cix143.
    1. Fischer Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, O'Brien KL, Campbell H, Black RE. Global burden of childhood pneumonia and diarrhoea. Lancet. 2013 Apr 20;381(9875):1405–1416. doi: 10.1016/S0140-6736(13)60222-6.
    1. Gilani Z, Kwong YD, Levine OS, Deloria-Knoll M, Scott JAG, O'Brien KL, Feikin DR. A literature review and survey of childhood pneumonia etiology studies: 2000-2010. Clin Infect Dis. 2012 Apr;54 Suppl 2:S102–8. doi: 10.1093/cid/cir1053.
    1. Ginsburg AS, May S, Nkwopara E, Ambler G, McCollum ED, Mvalo T, Phiri A, Lufesi N. Clinical Outcomes of Pneumonia and Other Comorbidities in Children Aged 2-59 Months in Lilongwe, Malawi: Protocol for the Prospective Observational Study "Innovative Treatments in Pneumonia". JMIR Res Protoc. 2019 Jul 29;8(7):e13377. doi: 10.2196/13377.
    1. Naghavi M, Wang H, Lozano R, Davis A, Liang X, Zhou M. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71. doi: 10.1016/s0140-6736(14)61682-2.
    1. Rhedin SA, Eklundh A, Ryd-Rinder M, Naucler P, Mårtensson A, Gantelius J, Zenk I, Andersson-Svahn H, Nybond S, Rasti R, Lindh M, Andersson M, Peltola V, Waris M, Alfvén T. Introducing a New Algorithm for Classification of Etiology in Studies on Pediatric Pneumonia: Protocol for the Trial of Respiratory Infections in Children for Enhanced Diagnostics Study. JMIR Res Protoc. 2019 Apr 26;8(4):e12705. doi: 10.2196/12705.
    1. Pneumonia Etiology Research for Child Health (PERCH) Study Group Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. Lancet. 2019 Aug 31;394(10200):757–779. doi: 10.1016/S0140-6736(19)30721-4.
    1. Chowdhury F, Shahid ASMSB, Ghosh PK, Rahman M, Hassan MZ, Akhtar Z, Muneer SM, Shahrin L, Ahmed T, Chisti MJ. Viral etiology of pneumonia among severely malnourished under-five children in an urban hospital, Bangladesh. PLoS One. 2020;15(2):e0228329. doi: 10.1371/journal.pone.0228329.
    1. Mathura S, Fuchsb A, Bielickia J, Van Daj, Sharlanda M. Antibiotic Use for Community Acquired Pneumonia (CAP) in Neonates and Children: 2016 Evidence Update. World Health Organization. 2016:1–23. doi: 10.1080/20469047.2017.1409455.
    1. Ashraf H, Mahmud R, Alam NH, Jahan SA, Kamal SM, Haque F, Salam MA, Gyr N. Randomized controlled trial of day care versus hospital care of severe pneumonia in Bangladesh. Pediatrics. 2010 Oct;126(4):e807–15. doi: 10.1542/peds.2009-3631.
    1. Ashraf H, Alam NH, Chisti MJ, Salam MA, Ahmed T, Gyr N. Observational follow-up study following two cohorts of children with severe pneumonia after discharge from day care clinic/hospital in Dhaka, Bangladesh. BMJ Open. 2012;2(4) doi: 10.1136/bmjopen-2012-000961.
    1. Chisti MJ, Salam MA, Smith JH, Ahmed T, Pietroni MAC, Shahunja KM, Shahid ASMSB, Faruque ASG, Ashraf H, Bardhan PK, Sharifuzzaman. Graham SM, Duke T. Bubble continuous positive airway pressure for children with severe pneumonia and hypoxaemia in Bangladesh: an open, randomised controlled trial. Lancet. 2015 Sep 12;386(9998):1057–65. doi: 10.1016/S0140-6736(15)60249-5.
    1. Ashraf H, Jahan SA, Alam NH, Mahmud R, Kamal SM, Salam MA, Gyr N. Day-care management of severe and very severe pneumonia, without associated co-morbidities such as severe malnutrition, in an urban health clinic in Dhaka, Bangladesh. Arch Dis Child. 2008 Jun;93(6):490–4. doi: 10.1136/adc.2007.118877.
    1. Fonseca W, Hoppu K, Rey LC, Amaral J, Qazi S. Comparing pharmacokinetics of amoxicillin given twice or three times per day to children older than 3 months with pneumonia. Antimicrob Agents Chemother. 2003 Mar;47(3):997–1001. doi: 10.1128/aac.47.3.997-1001.2003.
    1. Hazir T, Fox LM, Nisar YB, Fox MP, Ashraf YP, MacLeod WB, Ramzan A, Maqbool S, Masood T, Hussain W, Murtaza A, Khawar N, Tariq P, Asghar R, Simon JL, Thea DM, Qazi SA, New Outpatient Short-Course Home Oral Therapy for Severe Pneumonia Study Group Ambulatory short-course high-dose oral amoxicillin for treatment of severe pneumonia in children: a randomised equivalency trial. Lancet. 2008 Jan 05;371(9606):49–56. doi: 10.1016/S0140-6736(08)60071-9.
    1. Grant GB, Campbell H, Dowell SF, Graham SM, Klugman KP, Mulholland EK, Steinhoff M, Weber MW, Qazi S, World Health Organization Department of Child and Adolescent Health and Development Recommendations for treatment of childhood non-severe pneumonia. Lancet Infect Dis. 2009 Mar;9(3):185–96. doi: 10.1016/S1473-3099(09)70044-1.
    1. Lodha R, Kabra SK, Pandey RM. Antibiotics for community-acquired pneumonia in children. Cochrane Database Syst Rev. 2013 Jun 04;(6):CD004874. doi: 10.1002/14651858.CD004874.pub4.
    1. World Health Organization . World Health Organization. Geneva, Switzerland: World Health Organization; 2014. [2020-10-08]. Revised WHO Classification and Treatment of Pneumonia in Children at Health Facilities: Evidence Summaries. .
    1. World Health Organization . World Health Organization. Geneva, Switzerland: World Health Organization; 2013. [2020-10-08]. Pocket book of hospital care for children: guidelines for the management of common childhood illnesses.
    1. Sarmin M, Hossain MI, Islam SB, Alam NH, Sarker SA, Islam MM, Chisti MJ, Islam SMR, Mahfuz M, Ahmed T. Efficacy of a Green Banana-Mixed Diet in the Management of Persistent Diarrhea: Protocol for an Open-Labeled, Randomized Controlled Trial. JMIR Res Protoc. 2020 Mar 06;9(3):e15759. doi: 10.2196/15759.
    1. Ahmed T, Ali M, Ullah MM, Choudhury IA, Haque ME, Salam MA, Rabbani GH, Suskind RM, Fuchs GJ. Mortality in severely malnourished children with diarrhoea and use of a standardised management protocol. Lancet. 1999 Jun 05;353(9168):1919–22. doi: 10.1016/S0140-6736(98)07499-6.
    1. Shahrin L, Chisti M, Ahmed T. Primary and Secondary Malnutrition. In: Koletzko B, Bhatia J, Bhutta ZA, Cooper P, Makrides M, Uauy R, editors. Pediatric Nutrition in Practice. 2nd ed. World Review of Nutrition and Dietetics; vol 113. Basel, Switzerland: Karger Publishers; 2015. pp. 139–46.
    1. Shahrin L, Chisti MJ, Huq S, Nishath T, Christy MD, Hannan A, Ahmed T. Clinical Manifestations of Hyponatremia and Hypernatremia in Under-Five Diarrheal Children in a Diarrhea Hospital. J Trop Pediatr. 2016 Jun;62(3):206–12. doi: 10.1093/tropej/fmv100.
    1. Alam NH, Hamadani JD, Dewan N, Fuchs GJ. Efficacy and safety of a modified oral rehydration solution (ReSoMaL) in the treatment of severely malnourished children with watery diarrhea. J Pediatr. 2003 Nov;143(5):614–9. doi: 10.1067/S0022-3476(03)00500-6.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi